Cumberland Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $39.9M+5.4% YoYTTM through 30 Jun 2026
Net Income -$10.9MTTM through 30 Jun 2026
Free Cash Flow $683.9KTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 85.2% |
| EBITDA Margin | -13.8% |
| Operating Margin | -6.3% |
| Net Margin | -27.4% |
Returns
-11.7%ROE
-3.8%ROA
Balance Sheet Health
Debt / Equity0.21x
Current Ratio0.96x
Net Debt-$6.2Mnet cash position
Cash & Equivalents$3.9M
Quality Metrics
Altman Z-Score0.95
Piotroski F-Score4 / 9
FCF Margin1.7%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $44.5M
Diluted EPS-$0.73TTMFY2025: $-0.19
Dividend
No dividend
Capital Allocation
R&D Spend$5.6M
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sancuso | $11.9M | ||
| Kristalose | $10.5M | ||
| Vibativ | $9.5M | ||
| Caldolor | $4.7M | ||
| Talicia | $3.3M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.